FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.

BACKGROUND Less than 50% of all high-grade non-Hodgkin lymphoma (NHL) patients experience lasting disease-free survival. Risk-adapted treatment strategies require better tools for prediction of outcome. This investigation aimed to assess the value of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose (FDG-PET) after two to three cycles of chemotherapy for prediction of progression-free survival (PFS) and overall survival (OS). PATIENTS AND METHODS One hundred and twenty-one patients with high-grade NHL underwent FDG-PET. The therapy response on FDG-PET was correlated to PFS and OS using Kaplan-Meier survival analysis. Cox regression analyses were employed to test for independence of known pretreatment prognostic factors. RESULTS Fifty FDG-PET scans were negative, 19 scans showed minimal residual uptake (MRU), and 52 scans were positive. The estimated 5 year PFS was 88.8% for the PET-negative group, 59.3% for the MRU group, and 16.2% for the PET-positive group. Kaplan-Meier analyses showed strong associations between FDG-PET results and PFS (P <0.0001) and OS (P <0.01). Early interim FDG-PET was independent of the other prognostic factors. CONCLUSIONS Early interim FDG-PET is an accurate and independent predictor of PFS and OS. An early assessment of chemotherapy response with FDG-PET could provide the basis for selection of patients for alternative therapeutic strategies.

[1]  S. Barrans,et al.  Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. , 2002, Blood.

[2]  W. D. Ray.  4. Modelling Survival Data in Medical Research , 1995 .

[3]  T M Grogan,et al.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[4]  S. Pileri,et al.  Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Meland,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[6]  F. Kreuter,et al.  A Handbook of Statistical Analyses using SPSS , 2004 .

[7]  D. Weisenburger,et al.  Chemotherapy for diffuse large-cell lymphoma--rapidly responding patients have more durable remissions. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Zinzani.  Traditional Treatment Approaches in B-cell Non-Hodgkin's Lymphoma , 2003, Leukemia & lymphoma.

[9]  Roland Hustinx,et al.  Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  J. Vose,et al.  Current approaches to the management of non-Hodgkin's lymphoma. , 1998, Seminars in oncology.

[11]  D Front,et al.  Hodgkin disease: prediction of outcome with 67Ga scintigraphy after one cycle of chemotherapy. , 1999, Radiology.

[12]  N. Schmitz,et al.  Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  G. Canellos.  CHOP may have been part of the beginning but certainly not the end: issues in risk-related therapy of large-cell lymphoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Brian Everitt,et al.  A Handbook of Statistical Analyses Using SPSS , 2003 .

[15]  O. Hoekstra,et al.  Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  M. Cowles.  Modelling Survival Data in Medical Research (2nd ed.) (Book) , 2004 .

[17]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[18]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[19]  R. Marcus.  Current Treatment Options in Aggressive Lymphoma , 2003, Leukemia & lymphoma.

[20]  M Schwaiger,et al.  Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. , 1998, Blood.

[21]  Clifford Goodman,et al.  Society of Nuclear Medicine , 1988 .

[22]  V. Diehl,et al.  Early response to chemotherapy: a surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity? , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  D. Podoloff,et al.  The gallium scan predicts relapse in patients with Hodgkin's disease treated with combined modality therapy. , 1994, Annals of Oncology.

[24]  A. D. Van den Abbeele,et al.  Procedure guideline for gallium scintigraphy in the evaluation of malignant disease. Society of Nuclear Medicine. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  David Collett.  Modelling Survival Data in Medical Research , 1994 .

[26]  S. Hain,et al.  18-FDG-PET as a Prognostic Indicator in the Treatment of Aggressive Non-Hodgkin's Lymphoma-Comparison with CT , 2000, Leukemia & lymphoma.

[27]  Ash A. Alizadeh,et al.  Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. , 2004, The New England journal of medicine.

[28]  G. Jerusalem,et al.  Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. , 2000, Haematologica.

[29]  A. Hagenbeek,et al.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.

[30]  J. Leonard,et al.  PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  P. Dupont,et al.  Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  D. Zelterman,et al.  Gallium scans in the management of patients with Hodgkin's disease: a study of 101 patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  G. Canellos,et al.  Residual mass in lymphoma may not be residual disease. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.